[Skip to Content]
[Skip to Content Landing]
Views 472
Citations 0
Viewpoint
December 2018

Challenges in Adopting Level 1 Evidence for Multiparametric Magnetic Resonance Imaging as a Biomarker for Prostate Cancer Screening

Author Affiliations
  • 1Department of Urology, New York Presbyterian Hospital, Weill Cornell Medical College, New York, New York
  • 2Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
JAMA Oncol. 2018;4(12):1663-1664. doi:10.1001/jamaoncol.2018.4160

PRECISION is the first randomized clinical trial to demonstrate the value of an adjunctive test for men with elevated prostate-specific antigen (PSA) level. Multiparametric magnetic resonance imaging (mp-MRI) and MRI-ultrasound fusion targeted biopsy of suspicious lesions was reported to improve both the sensitivity and specificity of PSA testing, with fewer biopsies conducted but more high-grade cancers diagnosed in patients randomized to MRI compared with standard systematic prostate biopsy.1

×